var data={"title":"Lisinopril: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lisinopril: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6470?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lisinopril-drug-information\" class=\"drug drug_general\">see &quot;Lisinopril: Drug information&quot;</a> and <a href=\"topic.htm?path=lisinopril-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lisinopril: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709016\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">When pregnancy is detected, discontinue lisinopril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189191\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Prinivil;</li>\n      <li>Qbrelis;</li>\n      <li>Zestril</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50667930\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Prinivil;</li>\n      <li>Zestril</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053655\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Angiotensin-Converting Enzyme (ACE) Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053648\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=lisinopril-drug-information\" class=\"drug drug_general\">see &quot;Lisinopril: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note</b><b>:</b> Compounded and commercially available oral solutions available in multiple concentrations; precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension: Note:</b> Dosage must be titrated according to patient's response; <b>reduce dose by 50% in patients with hyponatremia, hypovolemia, severe CHF, decreased renal function, or receiving diuretics</b>. If possible, discontinue diuretics 2 to 3 days prior to initiating lisinopril; restart diuretic, if needed, after blood pressure is stable.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: Limited data available: Oral: Initial: 0.07 to 0.1 mg/kg/dose once daily; may increase at &ge;2 weeks intervals; maximum daily dose: 0.5 mg/kg/<b>day</b>; dosing based on a retrospective study of pediatric patients (n=123; 59 with hypertension; age range: 2 months to 18 years) which initiated therapy in the hospital to allow for close observation; median maximum dose in patients 1 month to &lt;2 years (n=13): 0.159 mg/kg/day (Raes 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;6 years: Limited data available: Oral: Initial: 0.07 to 0.1 mg/kg/dose once daily; maximum initial daily dose: 5 mg/<b>day</b>; increase dose at 1- to 2-week intervals; maximum daily dose: 0.6 mg/kg/<b>day</b> or 40 mg/<b>day</b> (NHBPEP 2004; NHLBI 2011; Raes 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years and Adolescents: Oral: Initial: 0.07 to 0.1 mg/kg/dose once daily; maximum initial daily dose: 5 mg/<b>day</b>; increase dose at 1- to 2-week intervals; maximum daily dose: 0.6 mg/kg/<b>day</b> or 40 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Proteinuria (mild IgA nephropathy):</b> Limited data available: Children &ge;4 years and Adolescents: Oral: Initial: 0.2 mg/kg/dose once daily (maximum initial dose: 10 mg) for 7 days, then increase to 0.4 mg/kg/dose once daily (maximum dose: 20 mg); dosing based on a pilot study of 40 pediatric patients (mean age: 11.4 years; range: 4 to 15 years) who during a 2-year treatment period showed statistically significant resolution of proteinuria in 82% of patients; five patients developed dizziness during treatment period and four of them required dosage reduction (50% to 75%) (Nakanishi 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal protection (diabetes mellitus or renal parenchymal disease):</b>  Limited data available: Infants, Children, and Adolescents: Oral: Initial: 0.1 mg/kg/dose once daily; maximum initial daily dose: 5 mg/day; dosing based on a retrospective study of pediatric patients (n=123 of which 60 had either DM or renal parenchymal disease; age range: 2 months to 18 years); the protocol included therapy initiation within the hospital to allow for close observation initially; median maximum dose: 0.135 mg/kg/day (Raes 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heart failure:</b> Oral: Initial: 2.5 to 5 mg once daily; then increase by no more than 10 mg increments at intervals no less than 2 weeks to the highest tolerated dose (maximum: 40 mg/day). Usual maintenance: 5 to 40 mg once daily; target dose: 20 to 40 mg once daily (ACCF/AHA [Yancy 2013]). <b>Note:</b> If patient has hyponatremia (serum sodium &lt;130 mEq/L) then initial dose should be 2.5 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b> Oral: Initial: 10 mg once daily (not maintained on a diuretic) or 5 mg once daily (maintained on a diuretic); adjust dose according to blood pressure response. Target dose (JNC 8 [James 2013]): 40 mg once daily; usual dosage range (ASH/ISH [Weber 2014]): 10 to 40 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Antihypertensive effect may diminish toward the end of the dosing interval especially with doses of 10 mg daily. An increased dose may aid in extending the duration of antihypertensive effect. Doses up to 80 mg daily have been used, but do not appear to give greater effect. If possible, consider discontinuing diuretics 2 to 3 days prior to initiating lisinopril; restart diuretic, if needed, after blood pressure is stable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myocardial infarction (within 24 hours in hemodynamically stable patients):</b> Oral: 5 mg immediately, then 5 mg at 24 hours, 10 mg at 48 hours, and 10 mg once daily for &ge;6 weeks. Patients should continue to receive standard treatments such as thrombolytics, aspirin, and beta-blockers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Children &ge;6 years and Adolescents &le;16 years: CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>:  No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 50% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 25% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis: Administer 25% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD):  Administer 25% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer 50% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Heart failure: CrCl &lt;30 mL/minute or serum creatinine &gt;3 mg/dL: Initial: 2.5 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypertension: Initial doses should be modified and upward titration should be cautious, based on response (maximum: 40 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;30 mL/minute: Initial: 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 30 mL/minute: Initial: 5 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Initial: 2.5 mg/day; dialyzable (50%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189166\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qbrelis: 1 mg/mL (150 mL) [contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prinivil: 5 mg, 10 mg, 20 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zestril: 2.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zestril: 5 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zestril: 10 mg, 20 mg, 30 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189151\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053659\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to food</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573852\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053658\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hypertension, either alone or in combination with other antihypertensive agents (FDA approved in ages &ge;6 years and adults); adjunctive therapy in treatment of heart failure (HF) (FDA approved in adults); treatment of acute myocardial infarction (MI) within 24 hours in hemodynamically stable patients to improve survival (FDA approved in adults); has also been used for the treatment of proteinuria associated with IgA nephropathy and for its reno-protective effects in patients with diabetes mellitus and renal parenchymal disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189246\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lisinopril may be confused with fosinopril, Lioresal, Lipitor, RisperDAL</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prinivil may be confused with Plendil, Pravachol, Prevacid, PriLOSEC, Proventil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zestril may be confused with Desyrel, Restoril, Vistaril, Zegerid, Zerit, Zetia, Zostrix, ZyPREXA</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acepril [Malaysia] may be confused with Accupril which is a brand name for quinapril [US]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acepril: Brand name for lisinopril [Malaysia], but also the brand name for captopril [Great Britain]; enalapril [Hungary, Switzerland] </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189244\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, flushing, hypotension, orthostatic effect, syncope, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Altered sense of smell, dizziness, fatigue, headache, paresthesia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, diaphoresis, erythema, pruritus, skin photosensitivity, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Diabetes mellitus, gout, hyperkalemia, SIADH</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, diarrhea, dysgeusia, flatulence, pancreatitis, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bone marrow depression, decreased hematocrit, decreased hemoglobin, eosinophilia, hemolytic anemia, increased erythrocyte sedimentation rate, leukocytosis, leukopenia, neutropenia, positive ANA titer, thrombocytopenia (mean decrease of 0.4 mg/dL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, diplopia, photophobia, vision loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen (transient), increased serum creatinine (transient), renal insufficiency (in patients with acute myocardial infarction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute renal failure, confusion, cutaneous pseudolymphoma, dehydration, fever, hallucination, hypoglycemia (diabetic patients on oral antidiabetic agents or insulin), hyponatremia, mood changes (including depressive symptoms), psoriasis, visual hallucination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189174\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to lisinopril, other ACE inhibitors, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; idiopathic or hereditary angioedema; concomitant use with aliskiren in patients with diabetes mellitus; coadministration with or within 36 hours of switching to or from a neprilysin inhibitor (eg, sacubitril).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Women who are pregnant, intend to become pregnant, or of childbearing potential and not using adequate contraception; breastfeeding; concomitant use with aliskiren, angiotensin receptor blockers (ARBs), or other ACE inhibitors in patients with moderate to severe renal impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>), hyperkalemia (&gt;5 mMol/L), or with heart failure who are hypotensive; concomitant use with ARBs or other ACE inhibitors in diabetic patients with end organ damage; pediatric patients &lt;6 years; pediatric patients 6 to 16 years of age with severe renal impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189155\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angioedema: At any time during treatment (especially following first dose), angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans may be at an increased risk. Risk may also be increased with concomitant use of mTOR inhibitor (eg, everolimus) therapy or a neprilysin inhibitor (eg, sacubitril). Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice or hepatitis, which may progress to fulminant hepatic necrosis (some fatal); discontinue if marked elevation of hepatic transaminases or jaundice occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1 to 4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Another ACE Inhibitor, captopril, has been associated with neutropenia with myeloid hypoplasia and agranulocytosis; anemia and thrombocytopenia have also occurred. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal impairment, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses). Effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation. Close monitoring of patients is required especially within the first few weeks of initial dosing and with dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation. Avoid use in hemodynamically unstable patients after acute MI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in BUN and serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small benign increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function (Bakris 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; consider baseline LFTs prior to initiating therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (ACCF/AHA [Gersh 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in preexisting renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. In a retrospective cohort study of elderly patients (&ge;65 years) with MI and impaired left ventricular function, administration of an ACE inhibitor was associated with a survival benefit, including patients with serum creatinine concentrations &gt;3 mg/dL (265 micromol/L) (Frances 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982). Some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Black patients: ACE inhibitors effectiveness is less in black patients than in non-black patients. In addition, ACE inhibitors cause a higher rate of angioedema in black than in non-black patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: In patients on chronic ACE inhibitor therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension. However, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis, 2011). Based on current research and clinical guidelines in patients undergoing noncardiac surgery, continuing ACE inhibitors is reasonable in the perioperative period. If ACE inhibitors are held before surgery, it is reasonable to restart postoperatively as soon as clinically feasible (ACC/AHA [Fleisher 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022358\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric patients, an isolated dry hacking cough lasting &gt;3 weeks was reported in seven of 42 pediatric patients (17%) receiving ACE inhibitors (von Vigier 2000); a review of pediatric randomized controlled ACE inhibitor trials reported a lower incidence of 3.2% (Baker-Smith 2010). Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299611\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189160\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12558&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: Angiotensin-Converting Enzyme Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II: Angiotensin-Converting Enzyme Inhibitors may enhance the therapeutic effect of Angiotensin II. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: In US labeling, use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives to the combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprotinin: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Angiotensin-Converting Enzyme Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): Angiotensin-Converting Enzyme Inhibitors may enhance the arrhythmogenic effect of Ciprofloxacin (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: Angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferric Gluconate: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferric Hydroxide Polymaltose Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Hydroxide Polymaltose Complex. Specifically, the risk for angioedema or allergic reactions may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gelatin (Succinylated): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gelatin (Succinylated). Specifically, the risk of a paradoxical hypotensive reaction may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gold Sodium Thiomalate: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Icatibant: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Dextran Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Angiotensin-Converting Enzyme Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pregabalin: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sacubitril: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Sacubitril. Specifically, the risk of angioedema may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: May enhance the hypotensive effect of Lisinopril.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189177\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.</b> Lisinopril crosses the placenta (Bhatt-Mehta 1993; Filler 2003).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. The use of these drugs in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Teratogenic effects may occur following maternal use of an ACE inhibitor during the first trimester, although this finding may be confounded by maternal disease. Because adverse fetal events are well documented with exposure later in pregnancy, ACE inhibitor use in pregnant women is not recommended (Seely 2014; Weber 2014). Infants exposed to an ACE inhibitor in utero should be monitored for hyperkalemia, hypotension, and oliguria. Oligohydramnios may not appear until after irreversible fetal injury has occurred. Exchange transfusions or dialysis may be required to reverse hypotension or improve renal function, although data related to the effectiveness in neonates is limited.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant and mother. ACE inhibitors are not recommended for the treatment of uncomplicated hypertension in pregnancy (ACOG 2013) and they are specifically contraindicated for the treatment of hypertension and chronic heart failure during pregnancy by some guidelines (Regitz-Zagrosek 2011). In addition, ACE inhibitors should generally be avoided in women of reproductive age (ACOG 2013). If treatment for hypertension or chronic heart failure in pregnancy is needed, other agents should be used (ACOG 2013; Regitz-Zagrosek 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053654\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, BUN, serum creatinine, renal function, urine dipstick for protein, serum potassium, WBC with differential, especially during first 3 months of therapy for patients with renal impairment and/or collagen vascular disease; monitor for angioedema and anaphylactoid reactions; hypovolemia and postural hypotension when beginning therapy, adjusting dosage, and on a regular basis throughout </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189154\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189173\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 1 hour; Peak effect: Hypotensive: Oral: ~6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Not metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pediatric patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">2 to 15 years: 20% to 36% (Hogg 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">6 to 16 years: ~28%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~25% (range: 6% to 60%); decreased to 16% with NYHA Class II-IV heart failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pediatric patients 6 months to 15 years: Median (range): 5 to 6 hours (Hogg 2007) </p>\n    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">Adults: ~7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189172\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> A lisinopril oral solution (1 mg/mL) is commercially available (Qbrelis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>1 mg/mL Oral Suspension </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">A 1 mg/mL lisinopril oral suspension may be made with tablets and a 1:1 mixture of Ora-Plus and Ora-Sweet. Crush ten 10 mg tablets in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a graduated cylinder; rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Store in amber plastic prescription bottles; label &quot;shake well.&quot; Stable for 13 weeks at room temperature or refrigerated (Nahata 2004).</p>\n    <div class=\"reference\">Nahata MC and Morosco RS. Stability of lisinopril in two liquid dosage forms. <i>Ann Pharmacother.</i> 2004;38(3):396-399.<span class=\"pubmed-id\">14742834</span></div>\r\n\n    <p style=\"text-indent:-2em;margin-left:4em;\">A 1 mg/mL lisinopril oral suspension may be made with tablets and a mixture of sodium citrate/citric acid oral solution or Cytra-2 diluent and Ora-Sweet SF. Place ten 20 mg tablets into an 8 ounce amber polyethylene terephthalate (PET) bottle and then add 10 mL purified water and shake for at least 1 minute. Gradually add 30 mL of sodium citrate/citric acid oral solution or Cytra-2 diluent and 160 mL of Ora-Sweet SF to the bottle and gently shake after each addition to disperse the contents. Store resulting suspension at &le;25&deg;C (77&deg;F) for up to 4 weeks. Label bottle &ldquo;shake well&rdquo; (Prinivil prescribing information 2016; Thompson 2003).</p>\n    <div class=\"reference\">Prinivil (lisinopril) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; October 2016.</div>\r\n\n    <div class=\"reference\">Thompson KC, Zhao Z, Mazakas JM, et al. Characterization of an extemporaneous liquid formulation of lisinopril. <i>Am J Health Syst Pharm.</i> 2003;60(1):69-74.<span class=\"pubmed-id\">12533979</span></div>\r\n\n    <p style=\"text-indent:-2em;margin-left:4em;\">A 1 mg/mL lisinopril oral suspension also be made with tablets, methylcellulose 1% with parabens, and simple syrup NF. Crush ten 10 mg tablets in a mortar and reduce to a fine powder. Add 7.7 mL of methylcellulose gel and mix to a uniform paste; mix while adding the simple syrup in incremental proportions to <b>almost</b> 100 mL; transfer to a graduated cylinder; rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Store in amber plastic prescription bottles; label &quot;shake well.&quot; Stable for 13 weeks refrigerated or 8 weeks at room temperature (Nahata 2004).</p>\n    <div class=\"reference\">Nahata MC and Morosco RS. Stability of lisinopril in two liquid dosage forms. <i>Ann Pharmacother.</i> 2004;38(3):396-399.<span class=\"pubmed-id\">14742834</span></div>\r\n\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>2 mg/mL Syrup </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 2 mg/mL lisinopril syrup may be made with powder (Sigma Chemical Company, St. Louis, MO) and simple syrup. Dissolve 1 g of lisinopril powder in 30 mL of distilled water. Mix while adding simple syrup in incremental proportions in a quantity sufficient to make 500 mL. Label &quot;shake well&quot; and &quot;refrigerate.&quot; Stable for 30 days when stored in amber plastic prescription bottles at room temperature or refrigerated. <b>Note:</b> Although no visual evidence of microbial growth was observed, the authors recommend refrigeration to inhibit microbial growth (Webster 1997).</p>\n    <div class=\"reference\">Webster AA, English BA, and Rose DJ. The stability of lisinopril as an extemporaneous syrup. <i>Intr J Pharmaceut Compound.</i> 1997;1:352-353.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189176\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Qbrelis Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (150 mL): $592.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Lisinopril Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $64.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $96.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $99.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $106.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $150.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $154.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Prinivil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (90): $172.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $179.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $191.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zestril Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (90): $1,373.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (90): $1,373.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $1,373.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $1,373.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (90): $1,373.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $1,373.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189179\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acemin (AT);</li>\n      <li>Acepril (BD, MY);</li>\n      <li>Acerbon (DE);</li>\n      <li>Acerdil (CL, EC, PE, PY);</li>\n      <li>Aklis (UY);</li>\n      <li>Alapril (IT);</li>\n      <li>Albigone (TR);</li>\n      <li>Alfaken (MX);</li>\n      <li>Auroliza (ET);</li>\n      <li>Cipril (HK, IN, LK);</li>\n      <li>Coric (DE);</li>\n      <li>Dapril (AE, BF, BJ, CI, ET, GH, GM, GN, KE, LR, LT, LV, MA, ML, MR, MT, MU, MW, MY, NE, NG, RU, SC, SD, SG, SK, SL, SN, TN, TR, TZ, UG, ZM, ZW);</li>\n      <li>Dapryl (UA);</li>\n      <li>Diroton (EE, LV, SK);</li>\n      <li>Dosteril (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Doxapril (AR);</li>\n      <li>ES (IN);</li>\n      <li>Eucor (EC);</li>\n      <li>Fersivag (MX);</li>\n      <li>Fibsol (AU);</li>\n      <li>Genopril (TW);</li>\n      <li>Hypersil (SG);</li>\n      <li>Inhitril (ID);</li>\n      <li>Inopril (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Irumed (HR, UA);</li>\n      <li>Lestace (IE);</li>\n      <li>Linipril (HU);</li>\n      <li>Linopril (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Linvas (IN);</li>\n      <li>Liprace (AU);</li>\n      <li>Lipril (BD, IN);</li>\n      <li>Lisdene (JO, MY, SG);</li>\n      <li>Lisibeta (DE);</li>\n      <li>Lisidigal (VN);</li>\n      <li>Lisigamma (DE);</li>\n      <li>Lisihexal (DE);</li>\n      <li>Lisino (QA);</li>\n      <li>Lisipril (CO, DO);</li>\n      <li>Lisir (TH);</li>\n      <li>Lisnoxl (LK);</li>\n      <li>Lisocard (JO);</li>\n      <li>Lisopress (BB, BM, BS, BZ, GY, HU, JM, NZ, SR, TT);</li>\n      <li>Lisopril (HK);</li>\n      <li>Lisoril (IN, SG);</li>\n      <li>Lispril (IE, TH);</li>\n      <li>Listril (ET, IN, LK);</li>\n      <li>Lizoryl (UA);</li>\n      <li>Longes (JP);</li>\n      <li>Nisirol (PY);</li>\n      <li>Nop (BD);</li>\n      <li>Noperten (ID);</li>\n      <li>Novatec (BE, LU, NL);</li>\n      <li>Odace (ID);</li>\n      <li>Omace (QA);</li>\n      <li>Pesatril (MX);</li>\n      <li>Presiten (DO);</li>\n      <li>Press (HU);</li>\n      <li>Prinil (CH);</li>\n      <li>Prinivil (AT, AU, BB, BG, BM, BR, BS, BZ, CZ, FR, GR, GY, HR, IT, JM, MX, PL, SR, TT, VE);</li>\n      <li>Ranolip (RO);</li>\n      <li>Safepril (TW);</li>\n      <li>Sinopren (ZA);</li>\n      <li>Sinopril (AE, BH, CY, EG, IQ, IR, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Skopryl (HR, UA);</li>\n      <li>Stril (BD);</li>\n      <li>Tensiphar (ID);</li>\n      <li>Tensopril (AR, IL);</li>\n      <li>Tensyn (CO);</li>\n      <li>Vitopril (BG);</li>\n      <li>Vivatec (DK, FI);</li>\n      <li>Zenoril (JO);</li>\n      <li>Zestan (IE, MT);</li>\n      <li>Zestril (AE, AU, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CR, CU, CY, DK, DO, EG, ES, ET, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, ID, IE, IQ, IR, JM, JO, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, OM, PA, PE, PH, PK, PT, QA, SA, SC, SD, SE, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, VN, YE, ZM, ZW);</li>\n      <li>Zinopril (QA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&rsquo; Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker-Smith CM, Benjamin DK Jr, Califf RM, et al, &quot;Cough in Pediatric Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials,&quot; <i>Clin Pharmacol Ther</i>, 2010, 87(6):668-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/20130570/pubmed\" target=\"_blank\" id=\"20130570\">20130570</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? <i>Arch Intern Med</i>. 2000;160(5):685-693.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/10724055/pubmed\" target=\"_blank\" id=\"10724055\">10724055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt-Mehta V and Deluga KS, &quot;Fetal Exposure to Lisinopril: Neonatal Manifestations and Management,&quot; <i>Pharmacotherapy</i>, 1993, 13(5):515-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/8247923/pubmed\" target=\"_blank\" id=\"8247923\">8247923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown NJ, Ray WA, Snowden M, et al, &ldquo;Black Americans Have an Increased Rate of Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema,&rdquo; <i>Clin Pharmacol Ther</i>, 1996, 60(1):8-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/8689816/pubmed\" target=\"_blank\" id=\"8689816\">8689816</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doane J and Stults B, &ldquo;Visual Hallucinations Related to Angiotensin-Converting Enzyme Inhibitor Use: Case Reports and Review,&rdquo; <i>J Clin Hypertens (Greenwich)</i>, 2013, 15(4):230-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/23551721/pubmed\" target=\"_blank\" id=\"23551721\">23551721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filler G, Wong H, Condello AS, et al, &quot;Early Dialysis in a Neonate With Intrauterine Lisinopril Exposure,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2003, 88(2):F154-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/12598508/pubmed\" target=\"_blank\" id=\"12598508\">12598508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. <i>Arch Intern Med</i>. 2000;160(17):2645-2650.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/10999979/pubmed\" target=\"_blank\" id=\"10999979\">10999979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(24):e783-e831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(23):2610-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hogg RJ, Delucchi A, Sakihara G, et al, &quot;A Multicenter Study of the Pharmacokinetics of Lisinopril in Pediatric Patients With Hypertension,&quot; <i>Pediatr Nephrol</i>, 2007, 22(5):695-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/17216247/pubmed\" target=\"_blank\" id=\"17216247\">17216247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nakanishi K, Iijima K, Ishikura K, et al, &quot;Efficacy and Safety of Lisinopril for Mild Childhood IgA Nephropathy: A Pilot Study,&quot; <i>Pediatr Nephrol</i>, 2009, 24(4):845-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/18825420/pubmed\" target=\"_blank\" id=\"18825420\">18825420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&rdquo; <i>Clinical Practice Guidelines</i>, 2011, National Institutes of Health. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &quot;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&quot; <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prinivil (lisinopril) [prescribing information]. Whitehouse Station, NJ: Merck and Co Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qbrelis (lisinopril) [prescribing information]. Greenwood Village, CO: Silvergate Pharmaceuticals; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raes A, Malfait F, Van Aken S, et al, &quot;Lisinopril in Paediatric Medicine: A Retrospective Chart Review of Long-Term Treatment in Children,&quot; <i>J Renin Angiotensin Aldosterone Syst</i>, 2007, 8(1):3-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/17487821/pubmed\" target=\"_blank\" id=\"17487821\">17487821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raia JJ Jr, Barone JA, Byerly WG, et al, &ldquo;Angiotensin-Converting Enzymes Inhibitors: A Comparative Review,&rdquo; <i>DICP</i>, 1990, 24(5):506-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/2188439/pubmed\" target=\"_blank\" id=\"2188439\">2188439</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seely EW, Ecker J. Chronic hypertension in pregnancy. <i>Circulation</i>. 2014;129(11):1254-1261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/24637432 /pubmed\" target=\"_blank\" id=\"24637432 \">24637432 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, et al. European Society of Gynecology (ESG). ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).<i> Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/21873418 /pubmed\" target=\"_blank\" id=\"21873418 \">21873418 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>Eur J Heart Fail</i>. 2010;12(8):767-778.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/20675664 /pubmed\" target=\"_blank\" id=\"20675664 \">20675664 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soffer B, Zhang Z, Miller K, et al, &quot;A Double-Blind, Placebo-Controlled, Dose-Response Study of the Effectiveness and Safety of Lisinopril for Children With Hypertension,&quot; <i>Am J Hypertens</i>, 2003, 16(10):795-800.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/14553956/pubmed\" target=\"_blank\" id=\"14553956\">14553956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Vigier RO, Mozzettini S, Truttmann AC, et al, &ldquo;Cough is Common in Children Prescribed Converting Enzyme Inhibitors,&rdquo; <i>Nephron</i>, 2000, 84(1):98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/10644922/pubmed\" target=\"_blank\" id=\"10644922\">10644922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zestril (lisinopril) [prescribing information]. Pine Brook, NJ: Almatica Pharma Inc; October 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisinopril-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12558 Version 278.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709016\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F189191\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50667930\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053655\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053648\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F189166\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F189151\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053659\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25573852\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053658\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F189246\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F189244\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F189174\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F189155\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022358\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299611\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F189160\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F189177\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053654\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F189154\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F189173\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F189172\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F189176\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F189179\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12558|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lisinopril-drug-information\" class=\"drug drug_general\">Lisinopril: Drug information</a></li><li><a href=\"topic.htm?path=lisinopril-patient-drug-information\" class=\"drug drug_patient\">Lisinopril: Patient drug information</a></li></ul></div></div>","javascript":null}